Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
27
ALNY Quote, Financials, Valuation and Earnings
Last price:
$243.38
Seasonality move
:
2.78%
Day range:
$236.70 - $243.90
52-week range:
$141.98 - $304.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.72x
P/B ratio:
969.73x
Volume:
253.1K
Avg. volume:
756.3K
1-year change:
27.34%
Market cap:
$31.4B
Revenue:
$1.8B
EPS (TTM):
-$2.62
Analysts' Opinion
-
Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 8 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $299.11, Alnylam Pharmaceuticals has an estimated upside of 22.96% from its current price of $243.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $178.00 representing 100% downside risk from its current price of $243.25.
Fair Value
-
According to the consensus of 20 analysts, Alnylam Pharmaceuticals has 22.96% upside to fair value with a price target of $299.11 per share.
ALNY vs. S&P 500
-
Over the past 5 trading days, Alnylam Pharmaceuticals has underperformed the S&P 500 by -4.18% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Alnylam Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alnylam Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Alnylam Pharmaceuticals reported revenues of $500.9M.
Earnings Growth
-
Alnylam Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Alnylam Pharmaceuticals reported earnings per share of -$0.87.
Enterprise value:
29.6B
EV / Invested capital:
28.05x
Price / LTM sales:
14.72x
EV / EBIT:
498.86x
EV / Revenue:
14.14x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1,843.87x
Price / Operating cash flow:
1,919.76x
Enterprise value / EBITDA:
206.58x
Gross Profit (TTM):
$1.8B
Return On Assets:
-8.43%
Net Income Margin (TTM):
-15.86%
Return On Equity:
--
Return On Invested Capital:
-36.66%
Operating Margin:
-15.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $960.9M | $1.7B | $2.1B | $750.5M | $500.9M | |
| Gross Profit | $805.7M | $1.4B | $1.8B | $666.2M | $415M | |
| Operating Income | -$791M | -$354.4M | -$188.1M | $213.9M | -$76.9M | |
| EBITDA | -$935.3M | -$285.1M | -$85.7M | $205.2M | -$47.2M | |
| Diluted EPS | -$9.77 | -$4.14 | -$2.62 | $1.15 | -$0.87 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $2.7B | $2.7B | $3B | $3.4B | |
| Total Assets | $3.3B | $3.5B | $3.5B | $3.8B | $4.2B | |
| Current Liabilities | $480.2M | $610.7M | $772.8M | $949.8M | $1.2B | |
| Total Liabilities | $2.1B | $2.7B | $3.6B | $4B | $4.2B | |
| Total Equity | $1.2B | $755.9M | -$67.6M | -$165.9M | $32.4M | |
| Total Debt | -- | $433.8M | $1B | $1B | $1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$559.4M | $2M | $56.6M | $359.4M | $43.7M | |
| Cash From Investing | -$104.1M | -$235.6M | -$304.6M | -$10.8M | -$30.3M | |
| Cash From Financing | $654.6M | $196.3M | $302.4M | $33.1M | $102.8M | |
| Free Cash Flow | -$631.7M | -$66.6M | $16.1M | $342.3M | $39.5M | |
ALNY
Sector
Market Cap
$31.4B
$45.6M
Price % of 52-Week High
79.91%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
27.34%
-31.35%
Beta (5-Year)
0.319
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$242.98
200-day SMA
Buy
Level
$221.39
Bollinger Bands (100)
Sell
Level
250.72 - 281.06
Chaikin Money Flow
Buy
Level
71.7M
20-day SMA
Sell
Level
$249.04
Relative Strength Index (RSI14)
Sell
Level
42.07
ADX Line
Buy
Level
7.22
Williams %R
Neutral
Level
-60.1781
50-day SMA
Sell
Level
$262.53
MACD (12, 26)
Sell
Level
-4.79
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
105.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.844)
Sell
CA Score
(Annual)
Level (-3.184)
Buy
Beneish M-Score
(Annual)
Level (-2.6252)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.0138)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Stock Forecast FAQ
In the current month, ALNY has received 11 Buy ratings 8 Hold ratings, and 1 Sell ratings. The ALNY average analyst price target in the past 3 months is $299.11.
-
Where Will Alnylam Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alnylam Pharmaceuticals share price will rise to $299.11 per share over the next 12 months.
-
What Do Analysts Say About Alnylam Pharmaceuticals?
Analysts are divided on their view about Alnylam Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alnylam Pharmaceuticals is a Sell and believe this share price will drop from its current level to $178.00.
-
What Is Alnylam Pharmaceuticals's Price Target?
The price target for Alnylam Pharmaceuticals over the next 1-year time period is forecast to be $299.11 according to 20 Wall Street analysts, 11 of them rate the stock a Buy, 1 rates the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is ALNY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alnylam Pharmaceuticals is a Buy. 11 of 20 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALNY?
You can purchase shares of Alnylam Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alnylam Pharmaceuticals shares.
-
What Is The Alnylam Pharmaceuticals Share Price Today?
Alnylam Pharmaceuticals was last trading at $243.38 per share. This represents the most recent stock quote for Alnylam Pharmaceuticals. Yesterday, Alnylam Pharmaceuticals closed at $243.25 per share.
-
How To Buy Alnylam Pharmaceuticals Stock Online?
In order to purchase Alnylam Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
